Nice one Wilbs
As opposed to the 2nd study of Kurtzberg
et al. (42), patient population in our study were highly pretreated and
refractory to previous treatments, which might have worsened
response.Some authors (42, 44, 49) have also showed that, when
MSCs were applied in an earlier stage of SR-aGVHD, the CR rates
were higher. For example, Le Blanc et al. (42), in their study of a
group of SR grade II-IV patients, described 55% CR and 16% PR.
For that reason, taking into account the side effects of second line
immunosuppression for GVHD and the good safety profile of MSCs
(even in severely affected children), earlier use of MSCs therapy
could be considered for patients with acute SR-GVHD.
Reg
Nice one WilbsAs opposed to the 2nd study of Kurtzberget al....
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.005(0.42%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.14 | $10.44M | 8.934M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 45750 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 1476 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
-0.005 ( 0.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.18 | $1.20 | $1.14 | 1465927 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| MSB (ASX) Chart |